Healthcare, Pharma & Life Sciences

Chennai – October 16, 2026 -- Zifo has been named a Gamechanger in Healthcare & Pharma in the enterprise segment at the Nasscom AI Gamechangers Awards 2026, for an AI service accelerator that speeds up master data creation for laboratory information management systems (LIMS).

Zifo's accelerator targets manual master data preparation in LIMS projects

Master data is foundational to configuring and implementing a LIMS. The source information is often scattered across PDFs, specifications, procedures and spreadsheets. Finding it, checking it and converting it into structured master data objects takes significant manual effort. The work must also meet the consistency, traceability and auditability that regulated environments expect.

London – October 16, 2026 -- The global ADHD drugs market will grow from USD 14.11 billion in 2025 to USD 22.79 billion by 2035, a compound annual growth rate of 4.91%, according to Credence Research Inc. The figures are the research firm's proprietary estimates, not audited sales totals.

North America holds 60% of value while Asia Pacific grows fastest at 6.34%

North America accounted for 60.0% of 2025 market value. Europe followed with 20.0%, Asia Pacific with 13.0%, Latin America with 4.0% and the Middle East and Africa with 3.0%.

Credence attributes Asia Pacific's 6.34% annual growth to better recognition and access in Japan, Australia and, increasingly, China, from a comparatively small revenue base. In Europe, reimbursement systems and lower net medicine prices restrain value per patient.

Santa Barbara – October 16, 2026 -- Artera, a healthcare patient-communications provider, ranked No. 3,000 on the 2026 Inc. 5000 list of the fastest-growing private U.S. companies, reporting 102 percent three-year revenue growth and marking its seventh consecutive appearance.

Artera joins TIME's 2026 HealthTech list with a 'Very High Performance' score

TIME named Artera to its World's Top HealthTech Companies of 2026 in the "Health Information and Management" category. TIME worked with data firm Statista, which evaluated companies on financial performance, reputation and online engagement.

Providence – October 16, 2026 -- Nabsys 2.0, LLC has released RepX, a cloud-based pipeline that can analyze up to 23 disease-associated repeat expansion loci in a single, low-cost run, according to the company.

RepX is available through the Nabsys Navigator cloud platform. It processes Electronic Genome Mapping (EGM) data generated on the OhmX Platform.

EGM reads single ultra-long DNA molecules without amplification or ligation

Repeat expansions are linked to numerous inherited disorders but remain difficult to characterize. EGM analyzes individual ultra-long DNA molecules without amplification or ligation, which avoids biases tied to those processes. Researchers can examine the distribution of expansion sizes and investigate repeat instability within each allele.

Atlanta – October 16, 2026 -- The U.S. Food and Drug Administration (FDA) has approved a once-daily autoinjector for UCB's ZILBRYSQ (zilucoplan), with complete dose delivery in 99.8% of 449 administrations, UCB said. Commercial availability is expected in Q1 2027.

The device is cleared for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. UCB (Euronext Brussels: UCB) describes ZILBRYSQ as the first and only macrocyclic peptide C5 inhibitor approved as a self-administered, once-daily subcutaneous autoinjector for gMG in the U.S.

Autoinjector adds a second self-administration route alongside the prefilled syringe

Before this approval, ZILBRYSQ was available only as a self-administered prefilled syringe (PFS). The autoinjector automatically delivers a pre-defined dose when activated against the skin. Patients or their care partners now have two portable options.

St. Petersburg, Florida – October 16, 2026 -- Attilio, a longevity platform launched in September 2026, has appointed Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging, as Co-Chairman. The company prices the Dr. Verdin Baseline Assessment(TM), built on his research, at $2,500 per member.

Verdin brings Buck Institute research access to Attilio's care model

The Buck Institute describes itself as the first independent biomedical research institute focused solely on aging and age-related disease. Founded in Novato, California, it helped establish the field known as geroscience.

Los Angeles – October 16, 2026 -- TORL BioTherapeutics has appointed Sandip Kapadia as Chief Financial Officer, a executive who has raised more than $2 billion in public capital for emerging biotechnology companies, and Eric Sievers, M.D., as Chief Medical Officer, completing a year-long expansion of its leadership team.

TORL prepares lead antibody-drug conjugate for late-stage development

The clinical-stage oncology company is advancing its antibody-based portfolio toward late-stage development and potential commercialization. Its lead asset, ixotatug vedotin (Ixo-V), is being evaluated in platinum-resistant ovarian cancer and other cancers that express CLDN6, including germ cell tumors, and in various combinations. Ixo-V has FDA Fast Track designation.

TORL describes Ixo-V as the first and only antibody-drug conjugate (ADC) that selectively targets Claudin 6 (CLDN6) using a proven monomethyl auristatin E (MMAE) linker-payload construct.

Berlin – October 16, 2026 -- Aignostics has launched HETA Clinical, a family of pan-cancer AI products aimed at the 10% to 20% of molecular tests that pathologists estimate fail because tissue contains too little tumor.

The first four products analyze whole slide H&E images across the pathology workflow, from intake and evaluation through to molecular testing. The company says the suite helps labs prioritize cases, cut turnaround time and confirm sufficient tumor content before molecular testing begins.

Four products target slide quality, tumor presence, mitoses and cellularity

HETA Quality Control measures slide quality before analysis and identifies a range of quality issues. HETA Tumor Detect annotates tumor regions and flags cases likely to contain tumor at scanning, so those cases are read first and additional stains can be ordered at intake.

Boston – October 16, 2026 -- Perceptive Discovery has become the first US provider able to run astatine-211 (At-211) radiopharmaceutical development studies, now available at its US and UK sites through a collaboration with Atley Solutions.

First Atley C100 module purifies At-211 at QMUL laboratory in London

At Perceptive Discovery's laboratory at Queen Mary University of London (QMUL), the first Atley C100 module in the collaboration is installed. It has been used to purify At-211 from an irradiated bismuth-209 target.

A second Atley C100 module is expected at the company's Needham, Massachusetts facility later this month. The Atley C100 is an automated manufacturing platform built specifically for At-211 radiopharmaceuticals.

Indianapolis – October 16, 2026 -- Eli Lilly and Company (NYSE: LLY) will publish its third-quarter 2026 financial results on October 16, 2026, and will discuss the numbers on a conference call the same day.

Lilly schedules a 10 a.m. Eastern call for investors and media

The conference call begins at 10 a.m. Eastern time. Lilly will use it to detail the company's financial performance for the quarter with the investment community and media.

Lilly opens the live webcast to the general public

Investors, media and the general public can follow the call through a live webcast. Lilly will post the access link on its investor relations website, and a replay will be available there after the call ends.

The announcement gives no financial figures, guidance or earnings metrics ahead of the October 29 release.